1
|
Deng D, Wang M, Su Y, Fang H, Chen Y, Su Z. Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy. J Med Chem 2024; 67:6810-6821. [PMID: 38613772 DOI: 10.1021/acs.jmedchem.4c00404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2024]
Abstract
Anti-PD-L1 immunotherapy, a new lung cancer treatment, is limited to a few patients due to low PD-L1 expression and tumor immunosuppression. To address these challenges, the upregulation of PD-L1 has the potential to elevate the response rate and efficiency of anti-PD-L1 and alleviate the immunosuppression of the tumor microenvironment. Herein, we developed a novel usnic acid-derived Iridium(III) complex, Ir-UA, that boosts PD-L1 expression and converts "cold tumors" to "hot". Subsequently, we administered Ir-UA combined with anti-PD-L1 in mice, which effectively inhibited tumor growth and promoted CD4+ and CD8+ T cell infiltration. To our knowledge, Ir-UA is the first iridium-based complex to stimulate the expression of PD-L1 by explicitly regulating its transcription factors, which not only provides a promising platform for immune checkpoint blockade but, more importantly, provides an effective treatment strategy for patients with low PD-L1 expression.
Collapse
Affiliation(s)
- Dongping Deng
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China
| | - Mengmeng Wang
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China
| | - Yan Su
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China
- Department of Rheumatology and Immunology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China
| | - Hongbao Fang
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China
| | - Yuncong Chen
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China
| | - Zhi Su
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, College of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China
| |
Collapse
|
2
|
Guo C, Wang KKA, Nolan EM. Investigation of Siderophore-Platinum(IV) Conjugates Reveals Differing Antibacterial Activity and DNA Damage Depending on the Platinum Cargo. ACS Infect Dis 2024; 10:1250-1266. [PMID: 38436588 DOI: 10.1021/acsinfecdis.3c00686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
The growing threat of bacterial infections coupled with the dwindling arsenal of effective antibiotics has heightened the urgency for innovative strategies to combat bacterial pathogens, particularly Gram-negative strains, which pose a significant challenge due to their outer membrane permeability barrier. In this study, we repurpose clinically approved anticancer agents as targeted antibacterials. We report two new siderophore-platinum(IV) conjugates, both of which consist of an oxaliplatin-based Pt(IV) prodrug (oxPt(IV)) conjugated to enterobactin (Ent), a triscatecholate siderophore employed by Enterobacteriaceae for iron acquisition. We demonstrate that l/d-Ent-oxPt(IV) (l/d-EOP) are selectively delivered into the Escherichia coli cytoplasm, achieving targeted antibacterial activity, causing filamentous morphology, and leading to enhanced Pt uptake by bacterial cells but reduced Pt uptake by human cells. d-EOP exhibits enhanced potency compared to oxaliplatin and l-EOP, primarily attributed to the intrinsic antibacterial activity of its non-native siderophore moiety. To further elucidate the antibacterial activity of Ent-Pt(IV) conjugates, we probed DNA damage caused by l/d-EOP and the previously reported cisplatin-based conjugates l/d-Ent-Pt(IV) (l/d-EP). A comparative analysis of these four conjugates reveals a correlation between antibacterial activity and the ability to induce DNA damage. This work expands the scope of Pt cargos targeted to the cytoplasm of Gram-negative bacteria via Ent conjugation, provides insight into the cellular consequences of Ent-Pt(IV) conjugates in E. coli, and furthers our understanding of the potential of Pt-based therapeutics for antibacterial applications.
Collapse
Affiliation(s)
- Chuchu Guo
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Kwo-Kwang A Wang
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Elizabeth M Nolan
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
3
|
Gabano E, Gariboldi MB, Marras E, Barbato F, Ravera M. Platinum(IV) combo prodrugs containing cyclohexane-1 R,2 R-diamine, valproic acid, and perillic acid as a multiaction chemotherapeutic platform for colon cancer. Dalton Trans 2023; 52:11349-11360. [PMID: 37530512 DOI: 10.1039/d3dt01876h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Abstract
The complex [PtCl2(cyclohexane-1R,2R-diamine)] has been combined in a Pt(IV) molecule with two different bioactive molecules (i.e., the histone deacetylase inhibitor 2-propylpentanoic acid or valproic acid, VPA, and the potential antimetastatic molecule 4-isopropenylcyclohexene-1-carboxylic acid or perillic acid, PA) in order to obtain a set of multiaction or multitarget antiproliferative agents. In addition to traditional thermal synthetic procedures, microwave-assisted heating was used to speed up their preparation. All Pt(IV) complexes showed antiproliferative activity on four human colon cancer cell lines (namely HCT116, HCT8, RKO and HT29) in the nanomolar range, considerably better than those of [PtCl2(cyclohexane-1R,2R-diamine)], VPA, PA, and the reference drug oxaliplatin. The synthesized complexes showed pro-apoptotic and pro-necrotic effects and the ability to induce cell cycle alterations. Moreover, the downregulation of histone deacetylase activity, leading to an increase in histone H3 and H4 levels, and the antimigratory activity, indicated by the reduction of the levels of matrix metalloproteinases MMP2 and MMP9, demonstrated the multiaction nature of the complexes, which showed biological properties similar to or better than those of VPA and PA, but at lower concentrations, probably due to the lipophilicity of the combo molecule that increases the intracellular concentration of the single components (i.e., [PtCl2(cyclohexane-1R,2R-diamine)], VPA and PA).
Collapse
Affiliation(s)
- Elisabetta Gabano
- Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Piazza Sant'Eusebio 5, 13100 Vercelli, Italy
| | - Marzia Bruna Gariboldi
- Dipartimento di Biotecnologie e Scienze della Vita (DBSV), Università dell'Insubria, via Dunant 3, Varese, Italy
| | - Emanuela Marras
- Dipartimento di Biotecnologie e Scienze della Vita (DBSV), Università dell'Insubria, via Dunant 3, Varese, Italy
| | - Francesca Barbato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | - Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| |
Collapse
|
4
|
Li Z, Qiao X, Liu XM, Shi SH, Qiao X, Xu JY. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment. Eur J Med Chem 2023; 250:115233. [PMID: 36863224 DOI: 10.1016/j.ejmech.2023.115233] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 02/21/2023] [Accepted: 02/21/2023] [Indexed: 02/24/2023]
Abstract
Cancer treatment requires the participation of multiple targets/pathways, and single approach is hard to effectively curb the proliferation and metastasis of carcinoma cells. In this work, we conjugated FDA-approved riluzole and platinum(II) drugs into a series of unreported riluzole-Pt(IV) compounds, which were designed to simultaneously target DNA, the solute carrier family 7 member 11 (SLC7A11, xCT), and the human ether a go-go related gene 1 (hERG1), to exert synergistic anticancer effect. Among them, c,c,t-[PtCl2(NH3)2(OH)(glutarylriluzole)] (compound 2) displayed excellent antiproliferative activity with IC50 value of 300-times lower than that of cisplatin in HCT-116, and optimal selectivity index between carcinoma and human normal liver cells (LO2). Mechanism studies indicated that compound 2 released riluzole and active Pt(II) species after entering cells to exhibit a prodrug behavior against cancer, which obviously increased DNA-damage and cell apoptosis, as well as suppressed metastasis in HCT-116. Compound 2 persisted in the xCT-target of riluzole and blocked the biosynthesis of glutathione (GSH) to trigger oxidative stress, which could boost the killing to cancer cells and reduce Pt-drug resistance. Meanwhile, compound 2 significantly inhibited invasion and metastasis of HCT-116 cells by targeting hERG1 to interrupt the phosphorylation of phosphatidylinositide 3-kinases/proteinserine-threonine kinase (PI3K/Akt), and reverse epithelial-mesenchymal transformation (EMT). Based on our results, the riluzole-Pt(IV) prodrugs studied in this work could be regarded as a new class of very promising candidates for cancer treatment compared to traditional platinum drugs.
Collapse
Affiliation(s)
- Zhe Li
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Xin Qiao
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Xiao-Meng Liu
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Shu-Hao Shi
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Xin Qiao
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Jing-Yuan Xu
- Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China; Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Tianjin Medical University, Tianjin, 300070, China.
| |
Collapse
|
5
|
The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH 3COO)Cl 2(NH 3) 2(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake. Bioinorg Chem Appl 2022; 2022:3698391. [PMID: 36620349 PMCID: PMC9822769 DOI: 10.1155/2022/3698391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 11/24/2022] [Accepted: 12/01/2022] [Indexed: 01/01/2023] Open
Abstract
The biological behavior of the axially unsymmetric antitumor prodrug (OC-6-44)-acetatodiamminedichloridohydroxidoplatinum(IV), 2, was deeply investigated and compared with that of analogous symmetric Pt(IV) complexes, namely, dihydroxido 1 and diacetato 3, which have a similar structure. The complexes were tested on a panel of human tumor cell lines. Complex 2 showed an anomalous higher cytotoxicity (similar to that of cisplatin) with respect to their analogues 1 and 3. Their reduction potentials, reduction kinetics, lipophilicity, and membrane affinity are compared. Cellular uptake and DNA platination of Pt(IV) complexes were deeply investigated in the sensitive A2780 human ovarian cancer cell line and in the corresponding resistant A2780cisR subline. The unexpected activity of 2 appears to be related to its peculiar cellular accumulation and not to a different rate of reduction or a different efficacy in DNA platination and/or efficiency in apoptosis induction. Although the exact mechanism of cell uptake is not fully deciphered, a series of naïve experiments indicates an energy-dependent, carrier-mediated transport: the organic cation transporters (OCTs) are the likely proteins involved.
Collapse
|
6
|
Guo C, Nolan EM. Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs to Escherichia coli. J Am Chem Soc 2022; 144:12756-12768. [PMID: 35803281 DOI: 10.1021/jacs.2c03324] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The global crisis of untreatable microbial infections necessitates the design of new antibiotics. Drug repurposing is a promising strategy for expanding the antibiotic repertoire. In this study, we repurpose the clinically approved anticancer agent cisplatin into a targeted antibiotic by conjugating its Pt(IV) prodrug to enterobactin (Ent), a triscatecholate siderophore employed by Enterobacteriaceae for iron (Fe) acquisition. The l-Ent-Pt(IV) conjugate (l-EP) exhibits antibacterial activity against Escherichia coli K12 and the uropathogenic isolate E. coli CFT073. Similar to cisplatin, l-EP causes a filamentous morphology in E. coli and initiates lysis in lysogenic bacteria. Studies with E. coli mutants defective in Ent transport proteins show that Ent mediates the delivery of l-EP into the E. coli cytoplasm, where reduction of the Pt(IV) prodrug releases the cisplatin warhead, causing growth inhibition and filamentation of E. coli. Substitution of Ent with its enantiomer affords the d-Ent-Pt(IV) conjugate (d-EP), which displays enhanced antibacterial activity, presumably because d-Ent cannot be hydrolyzed by Ent esterases and thus Fe cannot be released from this conjugate. E. coli treated with l/d-EP accumulate ≥10-fold more Pt as compared to cisplatin treatment. By contrast, human embryonic kidney cells (HEK293T) accumulate cisplatin but show negligible Pt uptake after treatment with either conjugate. Overall, this work demonstrates that the attachment of a siderophore repurposes a Pt anticancer agent into a targeted antibiotic that is recognized and transported by siderophore uptake machinery, providing a design strategy for drug repurposing by siderophore modification and heavy-metal "trojan-horse" antibiotics.
Collapse
Affiliation(s)
- Chuchu Guo
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Elizabeth M Nolan
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
7
|
Ravera M, Gabano E, McGlinchey MJ, Osella D. Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities. Dalton Trans 2022; 51:2121-2134. [PMID: 35015025 DOI: 10.1039/d1dt03886a] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Platinum(II)-based drugs are widely used for the treatment of solid tumors, especially in combination protocols. Severe side effects and occurrence of resistance are the major limitations to their clinical use. To overcome these drawbacks, a plethora of Pt(IV) derivatives, acting as anticancer prodrugs, have been designed, synthesized and preclinically (often only in vitro) tested. Here, we summarize the recent progress in the development and understanding of the chemical properties and biochemical features of these Pt(IV) prodrugs, especially those containing bioactive molecules as axial ligands, acting as multi-functional agents. Even though no such prodrugs have been yet approved for clinical use, many show encouraging pharmacological profiles. Thus, a better understanding of their features is a promising approach towards improving the available Pt-based anticancer agents.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, Alessandria, Italy.
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, Alessandria, Italy.
| | | | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, Alessandria, Italy.
| |
Collapse
|
8
|
Gabano E, Ferraris C, Osella D, Battaglia LS, Ravera M. Formulations of highly antiproliferative hydrophobic Pt(IV) complexes into lipidic nanoemulsions as delivery vehicles. Inorganica Chim Acta 2022. [DOI: 10.1016/j.ica.2022.120859] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
9
|
Schueffl H, Theiner S, Hermann G, Mayr J, Fronik P, Groza D, van Schonhooven S, Galvez L, Sommerfeld NS, Schintlmeister A, Reipert S, Wagner M, Mader RM, Koellensperger G, Keppler BK, Berger W, Kowol CR, Legin A, Heffeter P. Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chem Sci 2021; 12:12587-12599. [PMID: 34703544 PMCID: PMC8494022 DOI: 10.1039/d1sc03311e] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Accepted: 08/13/2021] [Indexed: 12/22/2022] Open
Abstract
Oxaliplatin is a very potent platinum(ii) drug which is frequently used in poly-chemotherapy schemes against advanced colorectal cancer. However, its benefit is limited by severe adverse effects as well as resistance development. Based on their higher tolerability, platinum(iv) prodrugs came into focus of interest. However, comparable to their platinum(ii) counterparts they lack tumor specificity and are frequently prematurely activated in the blood circulation. With the aim to exploit the enhanced albumin consumption and accumulation in the malignant tissue, we have recently developed a new albumin-targeted prodrug, which supposed to release oxaliplatin in a highly tumor-specific manner. In more detail, we designed a platinum(iv) complex containing two maleimide moieties in the axial position (KP2156), which allows selective binding to the cysteine 34. In the present study, diverse cell biological and analytical tools such as laser ablation inductively-coupled plasma mass spectrometry (LA-ICP-MS), isotope labeling, and nano-scale secondary ion mass spectrometry (NanoSIMS) were employed to better understand the in vivo distribution and activation process of KP2156 (in comparison to free oxaliplatin and a non-albumin-binding succinimide analogue). KP2156 forms very stable albumin adducts in the bloodstream resulting in a superior pharmacological profile, such as distinctly prolonged terminal excretion half-life and enhanced effective platinum dose (measured by ICP-MS). The albumin-bound drug is accumulating in the malignant tissue, where it enters the cancer cells via clathrin- and caveolin-dependent endocytosis, and is activated by reduction to release oxaliplatin. This results in profound, long-lasting anticancer activity of KP2156 against CT26 colon cancer tumors in vivo based on cell cycle arrest and apoptotic cell death. Summarizing, albumin-binding of platinum(iv) complexes potently enhances the efficacy of oxaliplatin therapy and should be further developed towards clinical phase I trials.
Collapse
Affiliation(s)
- Hemma Schueffl
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8a A-1090 Vienna Austria +43-1-40160-957555 +43-1-40160-57594
| | - Sarah Theiner
- Institute of Analytical Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 38 A-1090 Vienna Austria
| | - Gerrit Hermann
- Institute of Analytical Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 38 A-1090 Vienna Austria
| | - Josef Mayr
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
| | - Philipp Fronik
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
| | - Diana Groza
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8a A-1090 Vienna Austria +43-1-40160-957555 +43-1-40160-57594
| | - Sushilla van Schonhooven
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8a A-1090 Vienna Austria +43-1-40160-957555 +43-1-40160-57594
| | - Luis Galvez
- Institute of Analytical Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 38 A-1090 Vienna Austria
| | - Nadine S Sommerfeld
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
| | - Arno Schintlmeister
- Centre for Microbiology and Environmental Systems Science, Division of Microbial Ecology and Large-Instrument Facility for Environmental and Isotope Mass Spectrometry, University of Vienna Djerassiplatz 1 A-1030 Vienna Austria
| | - Siegfried Reipert
- Core Facility Cell Imaging and Ultrastructure Research, University of Vienna, University Biology Building (UBB) Djerassiplatz 1 A-1030 Vienna Austria
| | - Michael Wagner
- Centre for Microbiology and Environmental Systems Science, Division of Microbial Ecology and Large-Instrument Facility for Environmental and Isotope Mass Spectrometry, University of Vienna Djerassiplatz 1 A-1030 Vienna Austria
| | - Robert M Mader
- Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna Waehringer Guertel 18-20 1090 Vienna Austria
| | - Gunda Koellensperger
- Institute of Analytical Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 38 A-1090 Vienna Austria
| | - Bernhard K Keppler
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
- Research Cluster "Translational Cancer Therapy Research", University of Vienna, Medical University of Vienna Vienna Austria
| | - Walter Berger
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8a A-1090 Vienna Austria +43-1-40160-957555 +43-1-40160-57594
- Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna Waehringer Guertel 18-20 1090 Vienna Austria
| | - Christian R Kowol
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
- Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna Waehringer Guertel 18-20 1090 Vienna Austria
| | - Anton Legin
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna Waehringer Str. 42 A-1090 Vienna Austria +43-1-4277-852601 +43-1-4277-9526 +43-1-4277-52610 +43-1-4277-52611
| | - Petra Heffeter
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna Borschkegasse 8a A-1090 Vienna Austria +43-1-40160-957555 +43-1-40160-57594
- Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna Waehringer Guertel 18-20 1090 Vienna Austria
| |
Collapse
|
10
|
Xu Z, Wang Z, Deng Z, Zhu G. Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.213991] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
11
|
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines. Molecules 2021; 26:molecules26164740. [PMID: 34443328 PMCID: PMC8402032 DOI: 10.3390/molecules26164740] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 08/01/2021] [Accepted: 08/03/2021] [Indexed: 11/24/2022] Open
Abstract
Cisplatin is widely employed as a first-line chemotherapeutic agent for many solid tumors, including malignant pleural mesothelioma (MPM). However, its clinical use is limited by heavy side effects and acquired resistance, the latter being mainly related to enhanced DNA repair. Many clinical trials using combinations of platinum drugs and PARP-1 inhibitors (PARPis) have been carried out, with the hope that such combinations might lead to improved therapeutic efficacy against tumors. Here, the synthesis and efficacy in reducing MPM cell viability of four cisplatin-based Pt(IV) prodrugs containing the PARPi 3-aminobenzamide (3-ABA) fragment are described. The most promising conjugate is more effective than cisplatin or cisplatin/3-ABA combination, administered in equimolar doses, in inhibiting PARP-1 activity and inducing apoptosis in BRCA1/2 wild type MPM cells, grown as monolayer or as multicellular spheroids.
Collapse
|
12
|
Sharma KS, Vimalnath KV, Phadnis PP, Chakravarty R, Chakraborty S, Dash A, Vatsa RK. Facile Synthesis of a Pt(IV) Prodrug of Cisplatin and Its Intrinsically 195mPt Labeled Analog: A Step Closer to Cancer Theranostic. Indian J Nucl Med 2021; 36:140-147. [PMID: 34385784 PMCID: PMC8320819 DOI: 10.4103/ijnm.ijnm_188_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 10/14/2020] [Accepted: 11/23/2020] [Indexed: 11/23/2022] Open
Abstract
Background, Aims and Objectives: Cisplatin is extensively used in chemotherapy for treatment of a broad range of cancers. But its undesired side reactions with biomolecules that lead to severe side effects especially on kidney and nervous system, are limiting its clinical utility. To reduce its side effects, the kinetically inert Pt(IV) prodrug was recognized as an alternative approach from satisfactory results of preliminary experiments. But, its approval as anticancer drug for clinical use requires detailed investigations of its anticancer action and pharmacological pathways by employing its analogue which can be traced by a suitable technique. As a step closer towards translation of Pt(IV)-based prodrug from research to clinical level, a protocol for efficient synthesis of 195mPt-radiolabeled Pt(IV) prodrug was devised. Materials and Methods: In order to achieve the aim, we started synthesis from elemental platinum avoiding lengthy steps. The synthesis protocol was standardized on its cold analogue, as [PtCl2(NH3)2(OCOCH2CH2COOH)2] which has been characterized with nuclear magnetic resonance (1H, 13C{1H} and 195Pt{1H}) spectroscopy, microanalyses and cyclic voltammetry. Also, cytotoxicity of [PtCl2(OCOCH2CH2COOH)2(NH3)2] was evaluated against MCF-7 human breast cancer cell lines using cisplatin as test control. Results: Intrinsically, 195mPt-labeled analogue of prodrug was obtained with high radionuclidic and radiochemical purity. It was confirmed by chromatography and γ-ray spectrometry. Conclusion: The 195mPt-radiolabeled prodrug was synthesized in a facile manner. It can be utilized in evaluating the mechanism of anticancer action and pharmacokinetics by enabling synergistic use of molecular imaging and targeted drug delivery.
Collapse
Affiliation(s)
| | - K V Vimalnath
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India
| | - Prasad P Phadnis
- Chemistry Division, Bhabha Atomic Research Centre, Trombay, India.,Chemical Sciences, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.,Chemical Sciences, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.,Chemical Sciences, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.,Chemical Sciences, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Rajesh K Vatsa
- Chemistry Division, Bhabha Atomic Research Centre, Trombay, India.,Chemical Sciences, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| |
Collapse
|
13
|
Can the Self-Assembling of Dicarboxylate Pt(IV) Prodrugs Influence Their Cell Uptake? Bioinorg Chem Appl 2021; 2021:9489926. [PMID: 34239547 PMCID: PMC8235969 DOI: 10.1155/2021/9489926] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 06/01/2021] [Indexed: 12/11/2022] Open
Abstract
The possibility of spontaneous self-assembly of dicarboxylato Pt(IV) prodrugs and the consequences on their uptake in cancer cells have been evaluated in different aqueous solutions. Four Pt(IV) complexes, namely, (OC-6-33)-diacetatodiamminedichloridoplatinum(IV), Ace, (OC-6-33)-diamminedibutanoatodichloridoplatinum(IV), But, (OC-6-33)-diamminedichloridodihexanoatoplatinum(IV), Hex, and (OC-6-33)-diamminedichloridodioctanoatoplatinum(IV), Oct, have been dispersed in i) milliQ water, ii) phosphate buffered saline, and iii) complete cell culture media (RPMI 1640 or DMEM) containing fetal bovine serum (FBS). The samples have been analyzed by dynamic light scattering (DLS) to measure the size and distribution of the nanoparticles possibly present. The zeta potential offered an indication of the stability of the resulting aggregates. In the case of the most lipophilic compounds of the series, namely, Oct and to a lesser extent Hex, the formation of nanosized aggregates has been observed, in particular at the highest concentration tested (10 μM). The cell culture media had the effect to disaggregate these nanoparticles, mainly by virtue of their albumin content, able to interact with the organic chains via noncovalent (hydrophobic) interactions. For Oct, at the highest concentration employed for the uptake tests (10 μM), the combination between passive diffusion and endocytosis of the self-assembled nanoparticles makes the cellular uptake higher than in the presence of passive diffusion only. During the study of cellular uptake on A2780 ovarian cancer cells pretreated with cytochalasin D, a statistically significant inhibition of endocytosis was observed for Oct. In these experimental conditions, the relationship between uptake and lipophilicity becomes almost linear instead of exponential. Since Oct anticancer prodrug is active at nanomolar concentrations, where the aggregation in culture media is almost abolished, this phenomenon should not significantly impact its antiproliferative activity.
Collapse
|
14
|
NMR spectroscopy to study the fate of metallodrugs in cells. Curr Opin Chem Biol 2021; 61:214-226. [PMID: 33882391 DOI: 10.1016/j.cbpa.2021.03.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 03/08/2021] [Accepted: 03/10/2021] [Indexed: 11/21/2022]
Abstract
Metal-based drugs can modulate various biological processes and exhibit a rich variety of properties that foster their use in biomedicine and chemical biology. On the way to intracellular targets, ligand exchange and redox reactions can take place, thus making metallodrug speciation in vivo a challenging task. Advances in NMR spectroscopy have made it possible to move from solution to live-cell studies and elucidate the transport of metallodrugs and interactions with macromolecular targets in a physiological setting. In turn, the electronic properties and supramolecular chemistry of metal complexes can be exploited to characterize drug delivery nanosystems by NMR. The recent evolution of in-cell NMR methodology is presented with special emphasis on metal-related processes. Applications to paradigmatic cases of platinum and gold drugs are highlighted.
Collapse
|
15
|
Ferrari B, Roda E, Priori EC, De Luca F, Facoetti A, Ravera M, Brandalise F, Locatelli CA, Rossi P, Bottone MG. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Front Neurosci 2021; 15:589906. [PMID: 33828444 PMCID: PMC8019820 DOI: 10.3389/fnins.2021.589906] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 02/08/2021] [Indexed: 12/18/2022] Open
Abstract
Glioblastoma (GBM) is the most common tumor of the central nervous system. Current therapies, often associated with severe side effects, are inefficacious to contrast the GBM relapsing forms. In trying to overcome these drawbacks, (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(IV), also called Pt(IV)Ac-POA, has been recently synthesized. This new prodrug bearing as axial ligand (2-propynyl)octanoic acid (POA), a histone deacetylase inhibitor, has a higher activity due to (i) its high cellular accumulation by virtue of its high lipophilicity and (ii) the inhibition of histone deacetylase, which leads to the increased exposure of nuclear DNA, permitting higher platination and promoting cancer cell death. In the present study, we investigated the effects induced by Pt(IV)Ac-POA and its potential antitumor activity in human U251 glioblastoma cell line using a battery of complementary techniques, i.e., flow cytometry, immunocytochemistry, TEM, and Western blotting analyses. In addition, the synergistic effect of Pt(IV)Ac-POA associated with the innovative oncological hadrontherapy with carbon ions was investigated, with the aim to identify the most efficient anticancer treatment combination. Our in vitro data demonstrated that Pt(IV)Ac-POA is able to induce cell death, through different pathways, at concentrations lower than those tested for other platinum analogs. In particular, an enduring Pt(IV)Ac-POA antitumor effect, persisting in long-term treatment, was demonstrated. Interestingly, this effect was further amplified by the combined exposure to carbon ion radiation. In conclusion, Pt(IV)Ac-POA represents a promising prodrug to be incorporated into the treatment regimen for GBM. Moreover, the synergistic efficacy of the combined protocol using chemotherapeutic Pt(IV)Ac-POA followed by carbon ion radiation may represent a promising approach, which may overcome some typical limitations of conventional therapeutic protocols for GBM treatment.
Collapse
Affiliation(s)
- Beatrice Ferrari
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy
| | - Elisa Roda
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.,Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy
| | - Erica Cecilia Priori
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy
| | - Fabrizio De Luca
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy
| | - Angelica Facoetti
- National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy
| | - Mauro Ravera
- Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale "A. Avogadro", Alessandria, Italy
| | - Federico Brandalise
- Department of Fundamental Neurosciences (NEUFO), University of Geneva, Geneva, Switzerland
| | - Carlo Alessandro Locatelli
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy
| | - Paola Rossi
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy
| | - Maria Grazia Bottone
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy
| |
Collapse
|
16
|
Ravera M, Gabano E, Zanellato I, Rangone B, Perin E, Ferrari B, Bottone MG, Osella D. Cis,cis,trans-[Pt IVCl 2(NH 3) 2(perillato) 2], a dual-action prodrug with excellent cytotoxic and antimetastatic activity. Dalton Trans 2021; 50:3161-3177. [PMID: 33595015 DOI: 10.1039/d0dt04051g] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Two Pt(iv) conjugates containing one or two molecules of perillic acid (4-isopropenylcyclohexene-1-carboxylic acid), an active metabolite of limonene, were synthesized both with traditional and microwave-assisted methods and characterized. Their antiproliferative activity was tested on a panel of human tumor cell lines. In particular, cis,cis,trans-[PtIVCl2(NH3)2(perillato)2] exhibited excellent antiproliferative and antimetastatic activity on A-549 lung tumor cells at nanomolar concentrations. A number of in vitro biological tests were performed to decipher some aspects of its mechanism of action, including transwell migration and invasion as well as wound healing assay.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Tabrizi L, Thompson K, Mnich K, Chintha C, Gorman AM, Morrison L, Luessing J, Lowndes NF, Dockery P, Samali A, Erxleben A. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects. Mol Pharm 2020; 17:3009-3023. [PMID: 32628022 DOI: 10.1021/acs.molpharmaceut.0c00417] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The design, synthesis, characterization, and biological activity of a series of platinum(IV) prodrugs containing the axial ligand 3-(4-phenylquinazoline-2-carboxamido)propanoate (L3) are reported. L3 is a derivative of the quinazolinecarboxamide class of ligands that binds to the translocator protein (TSPO) at the outer mitochondrial membrane. The cytotoxicities of cis,cis,trans-[Pt(NH3)2Cl2(L3)(OH)] (C-Pt1), cis,cis,trans-[Pt(NH3)2Cl2(L3)(BZ)] (C-Pt2), trans-[Pt(DACH)(OX)(L3)(OH)] (C-Pt3), and trans-[Pt(DACH)(OX)(L3)(BZ)] (C-Pt4) (DACH: R,R-diaminocyclohexane, BZ: benzoate, OX: oxalate) in MCF-7 breast cancer and noncancerous MCF-10A epithelial cells were assessed and compared with those of cisplatin, oxaliplatin, and the free ligand L3. Moreover, the cellular uptake, ROS generation, DNA damage, and the effect on the mitochondrial function, mitochondrial membrane potential, and morphology were investigated. Molecular interactions of L3 in the TSPO binding site were studied using molecular docking. The results showed that complex C-Pt1 is the most effective Pt(IV) complex and exerts a multimodal mechanism involving DNA damage, potent ROS production, loss of the mitochondrial membrane potential, and mitochondrial damage.
Collapse
Affiliation(s)
- Leila Tabrizi
- School of Chemistry, National University of Ireland, Galway H91 TK33, Ireland
| | - Kerry Thompson
- Anatomy, School of Medicine, National University of Ireland, Galway H91 TK33, Ireland
| | - Katarzyna Mnich
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Chetan Chintha
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Adrienne M Gorman
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Liam Morrison
- Earth and Ocean Sciences, School of Natural Sciences and Ryan Institute, National University of Ireland, Galway H91 TK33, Ireland
| | - Janna Luessing
- Genome Stability Laboratory, Centre for Chromosome Biology, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Noel F Lowndes
- Genome Stability Laboratory, Centre for Chromosome Biology, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Peter Dockery
- Anatomy, School of Medicine, National University of Ireland, Galway H91 TK33, Ireland
| | - Afshin Samali
- Apoptosis Research Centre, School of Natural Sciences, National University of Ireland, Galway H91 TK33, Ireland
| | - Andrea Erxleben
- School of Chemistry, National University of Ireland, Galway H91 TK33, Ireland
| |
Collapse
|
18
|
Shahabadi N, Amiri S, Zhaleh H. Spectrophotometric and physicochemical studies on the interaction of a new platinum(IV) complex containing the drug pregabalin with calf thymus DNA. J COORD CHEM 2020. [DOI: 10.1080/00958972.2019.1710743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Nahid Shahabadi
- Department of Chemistry, Faculty of Science, Razi University, Kermanshah, Iran
- Medical Biology Research Center (MBRC), Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Sara Amiri
- Department of Chemistry, Faculty of Science, Razi University, Kermanshah, Iran
| | - Hossein Zhaleh
- Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
19
|
Sharma KS, Dubey AK, Koijam AS, Kumar C, Ballal A, Mukherjee S, Phadnis PP, Vatsa RK. Synthesis of 2-deoxy- d-glucose coated Fe 3O 4 nanoparticles for application in targeted delivery of the Pt( iv) prodrug of cisplatin – a novel approach in chemotherapy. NEW J CHEM 2020. [DOI: 10.1039/c9nj05989j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Pt(IV) prodrug of cisplatin was loaded on 2DG functionalized silica coated Fe3O4 nanoparticles. The formulation alone exhibited biocompatibility whereas Pt(IV) loaded formulation exhibited cytotoxicity comparable with cisplatin.
Collapse
Affiliation(s)
| | - Akhil K. Dubey
- Bio-Organic Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
| | - Arunkumar S. Koijam
- Radiopharmaceuticals Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
| | - Chandan Kumar
- Radiopharmaceuticals Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
| | - Anand Ballal
- Molecular Biology Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
| | - Sudip Mukherjee
- UGC-DAE Consortium for Scientific Research
- Mumbai Centre
- Mumbai-400 085
- India
| | - Prasad P. Phadnis
- Chemistry Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
- Homi Bhabha National Institute
| | - Rajesh K. Vatsa
- Chemistry Division
- Bhabha Atomic Research Centre
- Mumbai-400 085
- India
- Homi Bhabha National Institute
| |
Collapse
|
20
|
Wang MM, Xue XL, Sheng XX, Su Y, Kong YQ, Qian Y, Bao JC, Su Z, Liu HK. Unveiling the anti-cancer mechanism for half-sandwich and cyclometalated Ir(iii)-based complexes with functionalized α-lipoic acid. RSC Adv 2020; 10:5392-5398. [PMID: 35498295 PMCID: PMC9049077 DOI: 10.1039/c9ra10357k] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 01/19/2020] [Indexed: 12/18/2022] Open
Abstract
The introduction of LA improved the anticancer activity of the complex and helped overcome the cisplatin-resistance.
Collapse
Affiliation(s)
- Meng-Meng Wang
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Xu-Ling Xue
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Xi-Xi Sheng
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Yan Su
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Ya-Qiong Kong
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Yong Qian
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Jian-Chun Bao
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Zhi Su
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| | - Hong-Ke Liu
- Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
- College of Chemistry and Materials Science
- Nanjing Normal University
- Nanjing
- China
| |
Collapse
|
21
|
Ravera M, Zanellato I, Gabano E, Perin E, Rangone B, Coppola M, Osella D. Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen †. Int J Mol Sci 2019; 20:E3074. [PMID: 31238499 PMCID: PMC6627341 DOI: 10.3390/ijms20123074] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Revised: 06/20/2019] [Accepted: 06/22/2019] [Indexed: 02/06/2023] Open
Abstract
Cisplatin and several non-steroidal anti-inflammatory drugs (NSAIDs) have been proven to act synergistically or at least additively on several tumor cell lines. Dual-action cisplatin-based Pt(IV) combos containing ketoprofen and naproxen offer good antiproliferative performance on a panel of human tumor cell lines, including a malignant pleural mesothelioma (MPM) one, a very chemoresistant tumor. The main reason of the increased activity relies on the enhanced lipophilicity of these Pt(IV) conjugates that in turn promotes increased cellular accumulation. A quick Pt(IV)→Pt(II) reduction generates the active cisplatin metabolite. The NSAID adjuvant action seems to be almost independent from cyclooxygenase-2 (COX-2) expression in the tumor cells under investigation (lung A-549, colon HT-29, HCT 116, SW480, ovarian A2780, and biphasic MPM MSTO-211H), but it seems to rely (at least in part) on the activation of the NSAID activated gene, NAG-1 (a member of the transforming growth factor beta, TGF-β, superfamily), which has been suggested to be involved in NSAID antiproliferative activity.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Elena Perin
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Beatrice Rangone
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Marco Coppola
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria, Italy.
| |
Collapse
|
22
|
Ravera M, Gabano E, McGlinchey MJ, Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.04.025] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
23
|
Sabbatini M, Zanellato I, Ravera M, Gabano E, Perin E, Rangone B, Osella D. Pt(IV) Bifunctional Prodrug Containing 2-(2-Propynyl)octanoato Axial Ligand: Induction of Immunogenic Cell Death on Colon Cancer. J Med Chem 2019; 62:3395-3406. [PMID: 30879295 DOI: 10.1021/acs.jmedchem.8b01860] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The synthesis, characterization, and in vitro activity of a cyclohexane-1 R,2 R-diamine-based Pt(IV) derivative containing the histone deacetylase inhibitor rac-2-(2-propynyl)octanoato, namely, ( OC-6-44)-acetatodichlorido(cyclohexane-1 R,2 R-diamine)( rac-2-(2-propynyl)octanoato)platinum(IV), are reported together with those of its isomers containing enantiomerically enriched axial ligands. These Pt(IV) complexes showed comparable activity, of 2 orders of magnitude higher than reference drug oxaliplatin on three human (HCT 116, SW480, and HT-29) and one mouse (CT26) colon cancer cell lines. In vivo experiments were carried out on immunocompetent BALB/c mice bearing the same syngeneic tumor. The complex ( OC-6-44)-acetatodichlorido(cyclohexane-1 R,2 R-diamine)( rac-2-(2-propynyl)octanoato)platinum(IV) showed higher tumor mass Pt accumulation than oxaliplatin, due to its higher lipophilicity, with negligible nephro- and hepatotoxicities when administered intravenously. A remarkable tumor mass invasion by cytotoxic CD8+ T lymphocytes, following the Pt(IV) treatment, indicated a strong induction of immunogenic cell death.
Collapse
Affiliation(s)
- Maurizio Sabbatini
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Elena Perin
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Beatrice Rangone
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica , Università del Piemonte Orientale , Viale Michel 11 , 15121 Alessandria , Italy
| |
Collapse
|
24
|
Gabano E, Ravera M, Perin E, Zanellato I, Rangone B, McGlinchey MJ, Osella D. Synthesis and characterization of cyclohexane-1R,2R-diamine-based Pt(iv) dicarboxylato anticancer prodrugs: their selective activity against human colon cancer cell lines. Dalton Trans 2019; 48:435-445. [PMID: 30539948 DOI: 10.1039/c8dt03950j] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Three pairs of asymmetric dicarboxylato derivatives based on the cisplatin and oxaliplatin-like skeletons have been synthesized de novo or re-synthesized. The axial ligands consist of one medium-chain fatty acid (MCFA), namely clofibrate (i.e. 2-(p-chlorophenoxy)-2-methylpropionic acid, CA), heptanoate (HA) or octanoate (OA), respectively, and an inactive acetato ligand that imparts acceptable water solubility to such conjugates. Stability tests provided evidence for the partial formation of two hydrolyzed products, corresponding to two monoaqua diastereomers derived from the substitution of an equatorial chlorido ligand with a water molecule. The complexes have been tested on three different colon cancer cell lines having different histological history, and also on the cisplatin-sensitive A2780 ovarian cancer cell line for comparison. This allowed the evaluation not only of the increase in activity on passing from Pt(ii) to Pt(iv) derivatives, but also the selectivity towards colon cancer cells brought about by the cyclohexane-1R,2R-diamine carrier ligand.
Collapse
Affiliation(s)
- E Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Cai Y, Zhou L, Gao Y, Liu W, Shao Y, Zheng Y. Contribution of Base Damages to the Molecular Radiosensitization Mechanism of Platinum Chemotherapeutic Drugs. ChemistrySelect 2019. [DOI: 10.1002/slct.201803400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Yanming Cai
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| | - Limei Zhou
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| | - Yingxia Gao
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| | - Wenhui Liu
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| | - Yu Shao
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| | - Yi Zheng
- Research Institute of Photocatalysis, S; tate Key Laboratory of Photocatalysis on Energy and Environment; Fuzhou University; Fuzhou 350116 P.R. China
| |
Collapse
|
26
|
Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug. J Inorg Biochem 2018; 189:185-191. [PMID: 30312905 DOI: 10.1016/j.jinorgbio.2018.09.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 09/27/2018] [Accepted: 09/28/2018] [Indexed: 01/08/2023]
Abstract
Nonporous silica nanoparticles with an external shell containing the 3‑aminopropyl arm (SiNP) were further decorated with alginic acid (SiNP-ALG) as a potential biocompatible delivery system for Pt antitumor agents. Such particles were coupled with the prodrug (OC‑6‑44)‑acetato(β‑alaninato)diamminedichloridoplatinum(IV), 1, through the formation of amide bonds between the pendant carboxylate groups on SiNP-ALG and the free amino group of the complex. Cytosol extracted from tumor cells was able to quickly and efficiently reduce the Pt(IV) prodrug, and produces the active metabolite cisplatin. SiNP-ALG-Pt conjugate was more active than both cisplatin and 1, due to its more efficient cell uptake, whereas the SiNP-ALG unplatinated nanoparticles were deprived of any nonspecific toxicity.
Collapse
|
27
|
Gabano E, Ravera M, Zanellato I, Tinello S, Gallina A, Rangone B, Gandin V, Marzano C, Bottone MG, Osella D. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Trans 2018; 46:14174-14185. [PMID: 28984330 DOI: 10.1039/c7dt02928d] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The design, synthesis, characterization and biological properties of a Pt(iv) complex containing the very active inhibitor of histone deacetylase (2-propynyl)octanoic acid, POA, as an axial ligand are reported here. The title complex, namely (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(iv), 1, containing POA in racemic or in enantiomeric forms, was one/two orders of magnitude more active than cisplatin, depending on the chemo-sensitivity of the cancer cell lines. Moreover, 1 exhibited similar or even better antiproliferative activity than (OC-6-33)-diamminedichloridobis(2-propylpentanoato)platinum(iv), 2, containing two molecules of the well-known histone deacetylase inhibitor 2-propylpentanoic (valproic) acid. The high potency of 1 is likely due to its high cellular accumulation and to the synergism between the DNA-damaging cisplatin and the histone deacetylase inhibitor POA, both released upon the intracellular reduction of 1. Prodrug 1, after oral administration, caused an impressive reduction of the tumor mass (94%) in a model of solid tumor (murine Lewis lung carcinoma), compared to that of the control, whereas (intraperitoneal) cisplatin induced a tumor regression of 75% only. A good accumulation of 1 was observed in the tumor mass. The time course of the body weight attested that cisplatin induced elevated anorexia, whereas treatment with 1 did not induce significant body weight loss throughout the therapeutic experiment.
Collapse
Affiliation(s)
- Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Hua W, Zhao J, Hu W, Gou S. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action. J Inorg Biochem 2018; 186:17-23. [PMID: 29807243 DOI: 10.1016/j.jinorgbio.2018.05.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 05/03/2018] [Accepted: 05/23/2018] [Indexed: 02/08/2023]
Abstract
A novel compound, Cou-platin, composed of 7-hydroxycoumarin and a platinum(IV) moiety derived from cisplatin was designed and synthesized. Significantly, Cou-platin exhibited more potent in vitro antitumor activity against all tested cancer cell lines than that of cisplatin, which was mainly attributed to the liberation of cisplatin and 7-hydroxycoumarin upon reduction with a biomolecular agent. Besides, cellular accumulation of Cou-platin was dramatically increased among several cancer cells in contrast to cisplatin. Flow cytometry study revealed that Cou-platin arrested cell cycle at G2 phase and induced cell apoptosis. Western blots results indicated that it not only activated cell apoptosis pathway, but also inhibited extracellular regulated protein kinases/mitogen-activated protein kinase pathway. In vivo tests showed that Cou-platin, at equimolar dose to cisplatin, could inhibit tumor growth in nude mouse HCT116 tumor xenograft models almost as cisplatin and oxaliplatin, but with less toxicity.
Collapse
Affiliation(s)
- Wuyang Hua
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Jian Zhao
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Bio-medical Research, Southeast University, Nanjing 211189, China
| | - Weiwei Hu
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Bio-medical Research, Southeast University, Nanjing 211189, China
| | - Shaohua Gou
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Bio-medical Research, Southeast University, Nanjing 211189, China.
| |
Collapse
|
29
|
Espina M, Corte-Rodríguez M, Aguado L, Montes-Bayón M, Sierra MI, Martínez-Camblor P, Blanco-González E, Sierra LM. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure. Metallomics 2018; 9:564-574. [PMID: 28425536 DOI: 10.1039/c7mt00014f] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Cisplatin, one of the most extensively used metallodrugs in cancer treatment, presents the important drawback of patient resistance. This resistance is the consequence of different processes including those preventing the formation of DNA adducts and/or their quick removal. Thus, a tool for the accurate detection and quantitation of cisplatin-induced adducts might be valuable for predicting patient resistance. To prove the validity of such an assumption, highly sensitive plasma mass spectrometry (ICP-MS) strategies were applied to determine DNA adduct levels and intracellular Pt concentrations. These two metal-relative parameters were combined with an evaluation of biological responses in terms of genomic stability (with the Comet assay) and cell cycle progression (by flow cytometry) in four human cell lines of different origins and cisplatin sensitivities (A549, GM04312, A2780 and A2780cis), treated with low cisplatin doses (5, 10 and 20 μM for 3 hours). Cell viability and apoptosis were determined as resistance indicators. Univariate linear regression analyses indicated that quantitation of cisplatin-induced G-G intra-strand adducts, measured 1 h after treatment, was the best predictor for viability and apoptosis in all of the cell lines. Multivariate linear regression analyses revealed that the prediction improved when the intracellular Pt content or the Comet data were included in the analysis, for all sensitive cell lines and for the A2780 and A2780cis cell lines, respectively. Thus, a reliable cisplatin resistance predictive model, which combines the quantitation of adducts by HPLC-ICP-MS, and their repair, with the intracellular Pt content and induced genomic instability, might be essential to identify early therapy failure.
Collapse
Affiliation(s)
- Marta Espina
- Dpt. of Functional Biology (Genetic Area) and Oncology University Institute (IUOPA), University of Oviedo, Oviedo 33006, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Gabano E, Perin E, Fielden C, Platts JA, Gallina A, Rangone B, Ravera M. How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)] . Dalton Trans 2018; 46:10246-10254. [PMID: 28737785 DOI: 10.1039/c7dt01706e] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Oxidation of [Pt(II)Cl(terpy)]+ (terpy = 2,2':6',2''-terpyridine) has been attempted with several oxidizing agents and under different experimental conditions in order to obtain a Pt(iv) complex suitable for the conjugation to nanovectors to be used in drug delivery targeting for anticancer therapy. The best compromise in terms of yield and purity of the final complex was obtained by microwave-assisted reaction at 70 °C in 50% aqueous H2O2 for 2 h. Under these conditions the quantitative formation of [Pt(IV)Cl(OH)2(terpy)]+ was observed. The subsequent synthetic steps were, (i) functionalization of [Pt(IV)Cl(OH)2(terpy)]+ in the axial position with succinic anhydride to obtain [Pt(IV)Cl(OH)(succinato)(terpy)]+ and (ii) reaction of the latter with nonporous silica nanoparticles (SNPs) with an external shell containing primary amino groups to obtain a nanovector able to transport the Pt(iv) antitumor prodrug in the form of a conjugate Pt-SNP. Finally, the antiproliferative activity and cell accumulation of [Pt(II)Cl(terpy)]+, [Pt(IV)Cl(OH)2(terpy)]+, and the Pt-SNP conjugate were measured on three cancer cell lines. Despite highly effective accumulation of Pt-SNP in cells, a modest increase in activity was observed with respect to the molecular species. Further experiments showed that the Pt-SNP conjugate can release [Pt(II)Cl(terpy)]+ upon reduction, but this metabolite may undergo hydrolysis, and the resulting aquo complex could coordinate once again the free amino groups of the SNPs. In the resulting tetraamine form, the Pt(ii) complex conjugated to the SNPs cannot completely perform its antiproliferative activity.
Collapse
Affiliation(s)
- E Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | | | | | | | | | | | | |
Collapse
|
31
|
Gabano E, Ravera M, Trivero F, Tinello S, Gallina A, Zanellato I, Gariboldi MB, Monti E, Osella D. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. Dalton Trans 2018; 47:8268-8282. [DOI: 10.1039/c7dt04614f] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The cisplatin/clofibrato combos are multi-action Pt(iv) complexes active on a panel of human tumor cell lines, also under hypoxic conditions.
Collapse
Affiliation(s)
- Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Francesca Trivero
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Stefano Tinello
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Andrea Gallina
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Marzia B. Gariboldi
- Dipartimento di Biotecnologie e Scienze della Vita
- Università dell'Insubria
- 21052 Busto Arsizio
- Italy
| | - Elena Monti
- Dipartimento di Biotecnologie e Scienze della Vita
- Università dell'Insubria
- 21052 Busto Arsizio
- Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| |
Collapse
|
32
|
Mass spectrometry as a powerful tool to study therapeutic metallodrugs speciation mechanisms: Current frontiers and perspectives. Coord Chem Rev 2017. [DOI: 10.1016/j.ccr.2017.02.012] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
33
|
Novohradsky V, Zanellato I, Marzano C, Pracharova J, Kasparkova J, Gibson D, Gandin V, Osella D, Brabec V. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. Sci Rep 2017. [PMID: 28623355 PMCID: PMC5473904 DOI: 10.1038/s41598-017-03864-w] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center. Our results demonstrate that Pt(IV)diOA is a potent cytotoxic agent against many cancer cell lines (the IC50 values are approximately two orders of magnitude lower than those of clinically used cisplatin or Pt(IV) derivatives with biologically inactive axial ligands). Importantly, Pt(IV)diOA overcomes resistance to cisplatin, is significantly more potent than its branched Pt(IV) valproato isomer and exhibits promising in vivo antitumor activity. The potency of Pt(IV)diOA is a consequence of several factors including enhanced cellular accumulation correlating with enhanced DNA platination and cytotoxicity. Pt(IV)diOA induces DNA hypermethylation and reduces mitochondrial membrane potential in cancer cells at levels markedly lower than the IC50 value of free OA suggesting the synergistic action of platinum and OA moieties. Collectively, the remarkable antitumor effects of Pt(IV)diOA are a consequence of the enhanced cellular uptake which makes it possible to simultaneously accumulate high levels of both cisplatin and OA in cells. The simultaneous dual action of cisplatin and OA by different mechanisms in tumor cells may result in a markedly enhanced and unique antitumor effects of Pt(IV) prodrugs.
Collapse
Affiliation(s)
- Vojtech Novohradsky
- Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, CZ-61265, Brno, Czech Republic
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Universita del Piemonte Orientale, "A. Avogadro"Viale T. Michel 11, 15121, Alessandria, Italy
| | - Cristina Marzano
- Dipartimento di Scienze del Farmaco, Universita di Padova, Via Marzolo 5, 35131, Padova, Italy
| | - Jitka Pracharova
- Department of Biophysics, Centre of the Region Hana for Biotechnological Agricultural Research, Faculty of Science, Palacky University, 17. listopadu 12, CZ-77146, Olomouc, Czech Republic
| | - Jana Kasparkova
- Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, CZ-61265, Brno, Czech Republic
| | - Dan Gibson
- Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120, Israel
| | - Valentina Gandin
- Dipartimento di Scienze del Farmaco, Universita di Padova, Via Marzolo 5, 35131, Padova, Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Universita del Piemonte Orientale, "A. Avogadro"Viale T. Michel 11, 15121, Alessandria, Italy.
| | - Viktor Brabec
- Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, CZ-61265, Brno, Czech Republic.
| |
Collapse
|
34
|
Foteeva L, Matczuk M, Timerbaev A. Analytical methodology for determination of interactions between metallodrugs and DNA: A critical examination. Trends Analyt Chem 2017. [DOI: 10.1016/j.trac.2017.03.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Ravera M, Gabano E, Zanellato I, Gallina A, Perin E, Arrais A, Cantamessa S, Osella D. Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what? Dalton Trans 2017; 46:1559-1566. [DOI: 10.1039/c6dt03749f] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Comparison between the antiproliferative properties of a Pt(iv)-valproato complex and its metabolites indicates that the former is more active because it is unremoved from cells.
Collapse
Affiliation(s)
- M. Ravera
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Gabano
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - I. Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - A. Gallina
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Perin
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - A. Arrais
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - S. Cantamessa
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - D. Osella
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| |
Collapse
|
36
|
Ravera M, Gabano E, Zanellato I, Fregonese F, Pelosi G, Platts JA, Osella D. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs. Dalton Trans 2016; 45:5300-9. [PMID: 26903367 DOI: 10.1039/c5dt04905a] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We report studies of a novel series of Pt(IV) complexes exhibiting an asymmetric combination of acetylamido and carboxylato ligands in the axial positions. We demonstrate efficient synthesis of a series of analogues, differing in the alkyl chain length and hence lipophilicity, from a stable acetylamido/hydroxido complex formed by reaction of cisplatin with peroxyacetimidic acid (PAIA). NMR spectroscopy and X-ray crystallography confirm the identity of the resulting complexes, and highlight subtle differences in the structure and stability of acetylamido complexes compared to the equivalent acetato complexes. Reduction of acetylamido complexes, whether achieved chemically or electro-chemically, is significantly more difficult than that of acetate complexes, resulting in lower antiproliferative activity for shorter-chain complexes. For those with longer chains and hence greater cell uptake, this difference is negated and acetylamido complexes are as active as acetato analogues, both exhibiting antiproliferative potency (1/IC50) against A2780 ovarian cancer cells similar to that of cisplatin.
Collapse
Affiliation(s)
- Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Teresa Michel 11, 15121 Alessandria, Italy.
| | - Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Teresa Michel 11, 15121 Alessandria, Italy.
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Teresa Michel 11, 15121 Alessandria, Italy.
| | - Federico Fregonese
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Teresa Michel 11, 15121 Alessandria, Italy.
| | - Giorgio Pelosi
- Dipartimento di Chimica, Università di Parma, Parco Area delle Scienze, 17/A, 43124 Parma, Italy
| | - James A Platts
- School of Chemistry, Cardiff University, Park Place, Cardiff CF10 3AT, UK
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Teresa Michel 11, 15121 Alessandria, Italy.
| |
Collapse
|
37
|
May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs? J Inorg Biochem 2016; 167:27-35. [PMID: 27898344 DOI: 10.1016/j.jinorgbio.2016.11.024] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 11/09/2016] [Accepted: 11/16/2016] [Indexed: 12/11/2022]
Abstract
A small series of Pt(IV) prodrugs containing Gln-like (Gln=glutamine) axial ligands has been designed with the aim to take advantage of the increased demand of Gln showed by some cancer cells (glutamine addiction). In complex 4 the Gln, linked through the α-carboxylic group is recognized by the Gln transporters, in particular by the solute carrier transporter SLC1A5. All compounds showed cellular accumulation, as well as antiproliferative activity, related to their lipophilicity, as already demonstrated for the majority of Pt(IV) prodrugs, that enter cells mainly by passive diffusion. On the contrary, when the Gln concentration in cell medium is near or lower to the physiological value, complex 4 acts as a Trojan horse: it enters SLC1A5-overexpressing cells, where, upon reduction, it releases the active metabolite cisplatin and the Gln-containing ligand, thus preventing any possible extrusion by the L-type amino acid transporter LAT1. This selective mechanism could decrease off-target accumulation of 4 and, consequently, Pt-associated side-effects.
Collapse
|
38
|
Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes. Bioinorg Chem Appl 2016; 2016:2380540. [PMID: 27774043 PMCID: PMC5059510 DOI: 10.1155/2016/2380540] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Accepted: 09/08/2016] [Indexed: 12/29/2022] Open
Abstract
Phenanthriplatin, that is, (SP-4-3)-diamminechlorido(phenanthridine)platinum(II) nitrate, an effective antitumor cationic Pt(II) complex, was loaded on negatively charged dextran sulfate (DS) as a model vector for drug delivery via electrostatic interactions. The free complex and the corresponding conjugate with DS were tested on two standard human tumor cell lines, namely, ovarian A2780 and colon HCT 116, and on several malignant pleural mesothelioma cell lines (namely, epithelioid BR95, mixed/biphasic MG06, sarcomatoid MM98, and sarcomatoid cisplatin-resistant MM98R). The in vitro results suggest that the conjugate releases the active metabolite phenanthriplatin with a biphasic fashion. In these experimental conditions, the conjugate is slightly less active than free phenanthriplatin; but both exhibited antiproliferative potency higher than the reference metallodrug cisplatin and were able to overcome the acquired cisplatin chemoresistance in MM98R cells.
Collapse
|
39
|
Göschl S, Varbanov HP, Theiner S, Jakupec MA, Galanski MS, Keppler BK. The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. J Inorg Biochem 2016; 160:264-74. [PMID: 27055943 DOI: 10.1016/j.jinorgbio.2016.03.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 02/23/2016] [Accepted: 03/12/2016] [Indexed: 01/31/2023]
Abstract
The current study aims to elucidate the possible reasons for the significantly different pharmacological behavior of platinum(IV) complexes with cisplatin-, carboplatin- or nedaplatin-like cores and how this difference can be related to their main physicochemical properties. Chlorido-containing complexes are reduced fast (within hours) by ascorbate and are able to unwind plasmid DNA in the presence of ascorbate, while their tri- and tetracarboxylato analogs are generally inert under the same conditions. Comparison of the lipophilicity, cellular accumulation and cytotoxicity of the investigated platinum compounds revealed the necessity to define new structure-property/activity relationships (SPRs and SARs). The higher activity and improved accumulation of platinum(IV) complexes bearing Cl(-) in equatorial position cannot only be attributed to passive diffusion facilitated by their lipophilicity. Therefore, further platinum accumulation experiments under conditions where active/facilitated transport mechanisms are suppressed were performed. Under hypothermic conditions (4°C), accumulation of dichloridoplatinum(IV) complexes is reduced down to 10% of the amount determined at 37°C. These findings suggest the involvement of active and/or facilitated transport in cellular uptake of platinum(IV) complexes with a cisplatin-like core. Studies with ATP depletion mediated by oligomycin and low glucose partially confirmed these observations, but their feasibility was severely limited in the adherent cell culture setting.
Collapse
Affiliation(s)
- Simone Göschl
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Hristo P Varbanov
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria; Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
| | - Sarah Theiner
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Michael A Jakupec
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria.
| | - Mathea S Galanski
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Bernhard K Keppler
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| |
Collapse
|
40
|
Raveendran R, Braude JP, Wexselblatt E, Novohradsky V, Stuchlikova O, Brabec V, Gandin V, Gibson D. Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem Sci 2016; 7:2381-2391. [PMID: 29997781 PMCID: PMC6003606 DOI: 10.1039/c5sc04205d] [Citation(s) in RCA: 129] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 12/24/2015] [Indexed: 12/27/2022] Open
Abstract
The Pt(iv) derivative of cisplatin, ctc-[Pt(NH3)2(PhB)2Cl2], is a p53 independent very potent cytotoxic agent that kills cancer cells by triggering various cellular pathways.
Our study demonstrates that Pt(iv) derivative of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)2(PhB)2Cl2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(iv) derivatives of cisplatin with either two hydroxido, two acetato or two valproato ligands. The high potency of this compound (and some others) is due to several factors including enhanced internalization, probably driven by “synergistic accumulation” of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity. ctc-[Pt(NH3)2(PhB)2Cl2] inhibits 60–70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB. Mechanistically, ctc-[Pt(NH3)2(PhB)2Cl2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway. Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)2(PhB)2Cl2] may not depend of p53. Pt(iv) derivatives of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs. ctc-[Pt(NH3)2(PhB)2Cl2] is significantly more potent than its valproate analog ctc-[Pt(NH3)2(VPA)2Cl2]. These compounds combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.
Collapse
Affiliation(s)
- Raji Raveendran
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel
| | - Jeremy Phillip Braude
- Dipartimento di Scienze del Farmaco , Universita di Padova , Via Marzolo 5 , 35131 Padova , Italy .
| | - Ezequiel Wexselblatt
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel
| | - Vojtech Novohradsky
- Institute of Biophysics , Academy of Sciences of the Czech Republic, v.v.i. , Kralovopolska 135 , CZ-61265 Brno , Czech Republic
| | - Olga Stuchlikova
- Institute of Biophysics , Academy of Sciences of the Czech Republic, v.v.i. , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.,Department of Biophysics , Faculty of Science , Palacky University , 17. listopadu 12 , CZ-77146 Olomouc , Czech Republic
| | - Viktor Brabec
- Institute of Biophysics , Academy of Sciences of the Czech Republic, v.v.i. , Kralovopolska 135 , CZ-61265 Brno , Czech Republic
| | - Valentina Gandin
- Dipartimento di Scienze del Farmaco , Universita di Padova , Via Marzolo 5 , 35131 Padova , Italy .
| | - Dan Gibson
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel
| |
Collapse
|
41
|
Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs. Dalton Trans 2016; 45:17233-17240. [DOI: 10.1039/c6dt03133a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Conjugate Pt(iv)–silica nanoparticles exhibited better antiproliferative activity than cisplatin and Pt(iv) precursors, due to their more efficient cellular uptake.
Collapse
Affiliation(s)
- M. Ravera
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Gabano
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - I. Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Perin
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - A. Arrais
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - D. Osella
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| |
Collapse
|
42
|
Bergamini P, Marvelli L, Spirandelli G, Gallerani E. Synthesis, characterization and antiproliferative activity of amino- and DMSO complexes of platinum(II) containing l-carnitine. Inorganica Chim Acta 2016. [DOI: 10.1016/j.ica.2015.09.033] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|